CeriBell has a 1-year low of $23.00 and a 1-year high of $32.75. CeriBell ( NASDAQ:CBLL – Get Free Report ) last issued its earnings results on Tuesday, November 12th.

Behind the Bell is an interview series featuring CEOs, executives or founders, live from MarketSite on a company’s listing day or milestone celebration—generally in the moments after ringing ...

J.P. Morgan started Ceribell (CBLL) with an overweight rating, pointing to its recurring revenue business model with a gross ...

TD Cowen：维持CeriBell(CBLL.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至36.00美元。 Ceribell（CBLL.US）公司简介：CeriBell Inc 是一家商业阶段的 ...

As previously reported, BofA analyst Travis Steed initiated coverage of Ceribell (CBLL) with a Buy rating and $32 price target The company has a first-mover advantage with its rapid point of care ...

JPMorgan initiated coverage of Ceribell (CBLL) with an Overweight rating and $32 price target Ceribell has developed a ...

Ceribell, Inc. is a commercial-stage medical technology company, which focuses on transforming the diagnosis and management of patients with serious neurological conditions. Its products include ...

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients ...

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ...